Biomerica (NASDAQ:BMRA) and XORTX Therapeutics (NASDAQ:XRTX) Critical Analysis

XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Profitability This table compares XORTX Therapeutics and Biomerica’s net margins, return on equity and return on assets. | Net Margins | Return on Equity | Return on Assets | | | XORTX Therapeutics | N/A | -150.01% | -106.53% | | Biomerica | -96.49% | -98.14% | -70.42% | Earnings and Valuation This table compares XORTX Therapeutics and Biomerica”s gross revenue, earnings per share (EPS) and valuation. | Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | | | XORTX Therapeutics | N/A | N/A | -$2.66 million | ($2.63) | -0.77 | | Biomerica | $5.31 million | 0.96 | -$4.97 million | ($0.89) | -1.85 | XORTX Therapeutics has higher earnings, but lower revenue than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks. Institutional & Insider Ownership 0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 18.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Risk & Volatility XORTX Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Analyst Ratings This is a summary of current ratings and target prices for XORTX Therapeutics and Biomerica, as provided by MarketBeat. | Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | | | XORTX Therapeutics | 1 | 0 | 0 | 0 | 1.00 | | Biomerica | 1 | 0 | 0 | 0 | 1.00 | Biomerica has a consensus price target of $9.00, indicating a potential upside of 447.11%. Given Biomerica’s higher probable upside, analysts plainly believe Biomerica is more favorable than XORTX Therapeutics. Summary Biomerica beats XORTX Therapeutics on 7 of the 11 factors compared between the two stocks. About XORTX Therapeutics Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd. About Biomerica Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.